Medco Health Solutions (MHS - option chain) shares are rising today after the company reported earnings this morning, posting a third-quarter profit of $371.5 million, or 85 cents per share. Excluding one-time items, MHS earned 91 cents per share on revenue of $16.32 billion. Analysts had forecast a profit of 88 cents per share on revenue of $16.14 billion. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on MHS.

MHS opened this morning at $54.09. So far today the stock has hit a low of $53.60 and a high of $56.70. As of 12:15, MHS is trading at $56.59 up $4.22 (8.1%). The chart for MHS looks bullish and S&P gives MHS a positive 5 STARS (out of 5) strong buy ranking.

Analyst Upgrades

• Verisk (VRSK) was upgraded to outperform from market perform at Wells Fargo.
• Marriott (MAR) was upgraded to outperform from market perform at Bernstein.
• Jefferies upgraded Teekay (TK) and Tsakos Energy (TNP) to Buy from Hold.
• Cadence Design (CDNS) was upgraded to sector perform from underperform at RBC Capital.
• BofA/Merrill upgraded NV Energy (NVE) to buy from underperform and Education Realty Trust (EDR) to neutral from underperform.
• Men's Wearhouse (MW) was upgraded to buy from hold at Stifel.
• William Blair upgraded Atheros (ATHR) to outperform from market perform.
• Freeport McMoran (FCX) was upgraded to buy from hold at Argus.

Analyst Upgrades

• Piper Jaffray upgraded Edwards Lifesciences (EW) to overweight from neutral and raised its target price for shares to $77 from $53 after The New England Journal of Medicine reported the company's PARTNER Trial met primary endpoints.
• UBS upgraded Endo Pharmaceuticals (ENDP) to buy from neutral and raised its price target to $36 from $25. UBS is positive on Endo's creative strategic deals and believes the switch to Opana TRF from Opana ER will be easy. Additionally, the analyst believes pipeline expectations are very low.
• BMO Capital upgraded Nvidia (NVDA) to outperform from market perform based on expectations that share loss in the core GPU business will stop, Tegra momentum and valuation. The firm raised its price target to $16 from $9.
• FirstEnergy (FE) and Allegheny Energy (AYE) were upgraded to outperform from neutral at Credit Suisse.
• Mylan (MYL) was upgraded to conviction buy from buy at Goldman. Warner
• Chilcott (WCRX) was upgraded to overweight from equal weight at Morgan Stanley.

Analyst Upgrades

• Raymond James upgraded Research in Motion (RIMM) to outperform from market perform based on valuation. The firm has a $70 price target on the stock.
• Macquarie upgraded Halliburton (HAL) to outperform from neutral and has a $40 price target on the stock. The firm said recent pressure pumping activity is above their expectations and pricing has firmed.
• Canaccord upgraded Baldor Electric (BEZ) to buy from speculative buy, citing improving business trends and the upcoming mandatory transition to premium efficiency motors. The firm has a $47 price target on the stock.
• Wells Fargo upgraded Williams-Sonoma (WSM) to outperform from market perform.
• Medco Health (MHS) was upgraded to conviction buy from buy at Goldman.
• Repsol (REP) was upgraded to buy from neutral at BofA/Merrill.

Analyst Upgrades

• Barclays upgraded GlaxoSmithKline (GSK) to overweight from equal weight and said investor concerns regarding Advair and Avandia are overdone.
• Leerink upgraded Bristol-Myers (BMY) to outperform from market perform, citing management's pipeline execution. Shares were also upgraded at Citigroup this morning to buy from hold.
• Goldman upgraded Medco Health (MHS) to buy from neutral and raised its price target on shares to $76 from $67. The firm cites valuation and expectations that earnings will accelerate in 2H10 driven by a stronger generic outlook.
• U.S. Steel (X) was upgraded to neutral from sell at UBS.
• Blyth (BTH) was upgraded to hold from underperform at Jefferies.
• IPC The Hospitalist Co. (IPCM) was upgraded to buy from hold at Deutsche Bank.

Analyst Upgrades

• Baird upgraded Air Products (APD) to outperform from neutral on valuation following the sell-off after the company's bid for Airgas (ARG). The firm has an $89 price target on shares.
• JPMorgan upgraded Peabody Energy (BTU) to overweight from neutral as it believes the company is well positioned for 2010. The firm has a $50 price target on shares.
• Jefferies raised Adobe (ADBE) to buy from hold and has a $40 target on the stock. The firm believes concerns over the future of Flash are overblown and that shares of Adobe are attractive. Additionally, the firm expects CS5 to have a "decent" product cycle.
• Dell (DELL) was upgraded to buy from neutral at BofA/Merrill.
• SXC Health Solutions (SXCI) was upgraded to buy from hold at ThinkEquity.
• Harman (HAR) was upgraded to neutral from underperform at Credit Suisse.

TheStreet.com's Jim Cramer says we'll see a big dip lower, but watch these key stocks for underlying buying interest.

At last, a test, a test of the futures! That's what we have been looking for, one of these gigantic down openings like the old days, where it goes down and you stand there and you get pounded. That's what the market was, basically, from the top of 2007 until March -- a series of days where you came in and the futures were down so much that you knew they were going to go lower, except for the people who shorted it the night before and were taking profits.

Welcome home, bears!

TheStreet.com's Jim Cramer says if you wait for market conditions to reach perfection, you'll be waiting a long time.

You know what? I am going to wait until I am sure housing has turned before I buy the homebuilders like Lennar (NYSE: LEN) (Cramer's Take) and Pulte (NYSE: PHM) (Cramer's Take). I am going to wait until the foreclosures peak before I buy Bank of America (NYSE: BAC) (Cramer's Take) and Wells Fargo (NYSE: WFC) (Cramer's Take).

I am going to wait until unemployment goes down before I buy 3M (NYSE: MMM) (Cramer's Take) and Disney (NYSE: DIS) (Cramer's Take) and IBM (NYSE: IBM) (Cramer's Take) and Caterpillar (NYSE: CAT) (Cramer's Take).

TheStreet.com's Jim Cramer says health care has never been this cheap relative to the market in its history.

Health care's not done rallying. As President Obama prepared himself for claiming a great political victory, we are all recognizing that the single-payer, socialized medicine covering cradle-to-grave, 100% paid for by the rich, the fear that left all things health care in the P/E dustbin, is dead. That's not going to happen.

That leaves us with the biggest bargains the market has to offer.

Health care has never been this lowly valued relative to the market in its history. Remember, 98% of the time it trades at a meaningful premium. I think that many believe some of these moves (like the Celgene (NASDAQ: CELG) (Cramer's Take) move) is because of gigantic new drug finds. In fact, I think they just got too cheap and the only thing really meaningful about the Celgene rally came because one of its Revlimid studies was stopped for good results, actually a predictable event given how well the drug works on many different kinds of cancers.

Analyst upgrades:

• Citigroup upgraded shares of Consol Energy (NYSE: CNX) to Buy from Hold following the company's lowered guidance as 2009 is fully contracted with a 26% price increase. The firm raised its target to $40 from $38.
  
• Deutsche Bank upgraded AstraZeneca (NYSE: AZN) to Buy from Hold on valuation as it thinks the sell-off on the company's Q4 miss and cautious guidance is overdone.
  
• Wachovia upgraded Boston Scientific (NYSE: BSX) to Outperform from Market Perform because the firm thinks the outlook of the company's two main markets is improving. The firm believes the company's valuation is attractive. Thomas Weisel upgraded Boston Scientific to Overweight from Market Weight citing valuation and improving fundamentals.
• Goldman added MasterCard (NYSE: MA) to the Conviction Buy List.
  
• Accuray (NASDAQ: ARAY) was raised to Buy from Neutral at Piper Jaffray.
  
• KLA-Tencor (NASDAQ: KLAC) was upgraded to Buy from Neutral at Banc of America/Merrill.

Analyst upgrades:

• Jefferies upgraded Sonus Networks (NASDAQ: SONS) to Buy from Hold on valuation as they find the risk/reward compelling at current levels. Jefferies has a $2 target on the stock.
  
• Dresdner upgraded HSBC (NYSE: HBC) to Buy from hold on valuation as they believe the dividend cut is fully priced in at current levels.
  
• JP Morgan upgraded Barnes & Noble (NYSE: BKS) to Neutral from Underweight on valuation as they recommend short positions take profits at current levels.
• Kellogg (K) was raised to Buy from Neutral at UBS.
  
• RPM, Inc (NYSE: RPM) and Valspar (NYSE: VAL) were upgraded at KeyBanc to Buy from Hold.
  
• Omnicare (NYSE: OCR) was upgraded to Overweight from Equal Weight at Barclays.

Analyst downgrades:

• Jefferies downgraded Dune Energy (AXE: DNE) to Underperform from Hold to reflect weak commodity prices and the company's reduced financial flexibility. The firm lowered its target price to 10c from 30c.
• Baird downgraded NeuStar (NYSE: NSR) to Neutral from Outperform and lowered their target to $20 from $22 based on 2009 revenue concerns and the CFO's departure.
  
• UBS cut Viacom (NYSE: VIA) to Neutral from Buy and lowered its target to $18 from $27. The firm believes advertising declines will be worst than expected and that Film expectations are too high.
• Goldcorp (NYSE: GG) was lowered to Neutral from Overweight at JP Morgan.
  
• Kindred Healthcare (NYSE: KND) and Tenet Healthcare (THC) were downgraded at Barclays to Equal Weight from Overweight.
  
• Cynosure (NASDAQ: CYNO) was downgraded to Hold from Buy at Citigroup.

Analyst initiations:

• Keefe Bruyette believes Blackstone's (NYSE: BX) operating results and cash flow generation are likely to remain depressed well into 2009 given the weakening economy. The firm started shares with a Market Perform rating and $6 target.
  
• Oppenheimer views Brinks (NYSE: BCO) as a pure-play secure logistics company and feels it is well positioned to take advantage of a recent decline in acquisition prices. The firm has an Outperform rating and $32 target on the stock.
• Kellogg (NYSE: K) was initiated with a Buy rating and $52 target at Janney Montgomery.
• Avery Dennison (NYSE: AVY) was started at Barclays with an Equal Weight rating.
• Medco Health (NYSE: MHS) was initiated with a Market Perform rating and $59 target at Bernstein.

The market's choppy/consolidating tone, combined with the slow-growth/no-growth U.S. economy, suggests it is prudent to add a defensive stock or two to your portfolio, and with the aforementioned in mind, Medco Health Solutions is worth a review.

Medco Health Solutions (NYSE: MHS) is one of the largest U.S. pharmacy benefit managers, with services provided to client/member PBMs and physicians/pharmacies. (Note: Medco Health's shares split 2-for-1 on January 10, 2008.)

Analysts like Medco's high account retention, new business wins, economies of scale, and the company's entry into the Medicare Part B segment with its acquisition of PolyMedica.

MOST NOTEWORTHY: Smith International, Cerner and Coach were today's noteworthy upgrades:

• JP Morgan upgraded Smith International (NYSE: SII) to Overweight from Neutral citing better risk/reward vs. group, and upside to estimates from Latin America drilling and its deepwater rig fleet. Note that Oppenheimer downgraded shares of SII based on valuation.
  
• Jefferies believes Cerner Corp. (NASDAQ: CERN) in-line results and solid domestic bookings could alleviate the pressure on shares. Shares were raised to Buy from Hold.
  
• Shares of Coach Inc. (NYSE: COH) were raised to Buy from Hold at Citigroup, citing sales stabilization and compelling valuation.

OTHER UPGRADES:

• Medco Health (NYSE: MHS) was upgraded at Oppenheimer to Outperform from Perform.
  
• ThinkPanmure raised VMware Inc. (NYSE: VMW) to Buy from Accumulate.
  
• SunTrust Banks (NYSE: STI) was upgraded to Market Perform from Underperform at Keefe Bruyette.

MOST NOTEWORTHY: National City, Syntax Brillian and Medco Health were today's noteworthy upgrades:

• Deutsche Bank upgraded shares of National City (NYSE: NCC) to Buy from Sell on valuation as they believe their $9.00 target is in-line with the company's franchise value.
  
• Baird upgraded Syntax Brillian (NASDAQ: BRLC) to Outperform from Neutral based on recently announced strategic initiatives and valuation.
  
• Jefferies upgraded shares of Medco Health (NYSE: MHS) to Buy from Hold as they believe the company's renewed PBM contract with United Healthcare (NYSE: UNH) removes a major overhang.

OTHER UPGRADES:

• Friedman Billings raised Downey Financial (NYSE: DSL) to Market Perform from Underperform.
  
• Volterra (VNASDAQ: LTR) was raised to Buy from Neutral at Piper.
  
• Alliance Data (NYSE: ADS) was raised at JP Morgan to Overweight from Neutral.

Sometimes our biggest medical emergency is the cost of the drugs we need to treat our physical ailments. There is a firm in Franklin Lakes, New Jersey, that actively pursues initiatives to cut increasing drug costs and it has some clout. It is the nation's leading pharmacy benefit manager and operates the country's largest mail order pharmacy.

Medco Health Solutions (NYSE: MHS) serves some 65 million members in the U.S. and Puerto Rico. Patients fill their prescription needs through a network of close to 60,000 pharmacies, a mail-order program, or the company's online pharmacy. Medco helps contain pharmacy health care costs for private and public employers, health plans, labor unions, government agencies, and individuals served by the Medicare Part D Prescription Drug Program. Cigna (NYSE: CI) and Express Scripts (NASDAQ: ESRX) are major competitors. IBM (NYSE: IBM) is a major customer.